Jeffrey (Jeff) Knapp has been named Chief Operating Officer. In this newly created role, Mr. Knapp will continue to lead the build out of the sales and marketing organization, and will also oversee commercial operations, manufacturing, corporate development, medical affairs, alliance management and contracts. Mr. Knapp joined Adamas as Chief Commercial Officer at the beginning of 2014.

He brings more than 25 years of commercial and operations experience in the pharmaceutical/biotechnology industry. Prior to Adamas, Mr. Knapp spent seven years as the Chief Commercial Officer for Affymax where he was responsible for building its U.S. commercial organization and leading the launch of the company's first product for the treatment of anemia. William (Bill) J. Dawson has been named Chief Financial Officer, replacing Anthony (Tony) Rimac.

Mr. Dawson will be responsible for financial strategy, financial planning and analysis, accounting, compliance, and SEC reporting and will play a key role in investor relations, corporate strategy and planning. Mr. Dawson was most recently a consultant to a number of companies, including Adamas. Previously he served as Chief Financial Officer at Catalyst Biosciences, Inc., from 2010 to 2012.

Both Mr. Knapp and Mr. Dawson will report to Gregory Went, PhD., Chairman and Chief Executive Officer.